Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 11/14/24 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
139 |
| 08/08/24 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
113 |
| 05/15/24 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
110 |
| 11/09/23 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
116 |
| 08/10/23 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
114 |
| 05/11/23 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
127 |
| 11/10/22 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
151 |
| 08/11/22 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
105 |
| 05/12/22 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
101 |
| 11/01/21 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
106 |
